Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.

ABSTRACT:

Purpose

The combination of taxanes and anthracyclines is still the mainstay of chemotherapy for early breast cancer. Capecitabine is an active drug with a favorable toxicity profile, showing strong anti-tumor activity against metastatic breast cancer. This trial assessed the efficacy and safety of the TX regimen (docetaxel and capecitabine) and compared it with the TE (docetaxel and epirubicin) regimen in locally advanced or high risk early HER2-negative breast cancer.

Patients and methods

This randomized clinical trial was conducted at five academic centers in China. Eligible female patients were randomly assigned (1:1) to the TX (docetaxel 75 mg/m² d1 plus capecitabine 1000 mg/m² twice d1-14, q3w) or TE (docetaxel 75 mg/m² d1 plus epirubici

SUBMITTER: Yang H 

PROVIDER: S-EPMC9795638 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature